 The schedule of treatment includes vinorelbine 30 mgm2 on days 1 8 every 21 days and trastuzumab 8 mgkg on day 1 and then 6 mgkg every 21 days. Vinorelbine is planned for maximum 9 cycles, while trastuzumab can be continued until progression. This study is a single-stage phase 2 design, and patients eligible for response evaluation are required. 